PharmaCyte Biotech, Inc. (PMCB) stock
PMCBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
$5.42−0.15 (-2.69%)
Close on Nov 17, 2026Market cap $58.19MP/E –Yield –
PharmaCyte Biotech operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
PharmaCyte Biotech's operating cash flow for the twelve months ending Apr 30, 2026 was -$5.15M. For fiscal 2026 it was -$5.15M. The highest annual figure on record is -$225.23K in fiscal 2011.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | -$5.15M | – |
| FY2025 | Apr 30, 2025 | -$2.98M | – |
| FY2024 | Apr 30, 2024 | -$2.15M | – |
| FY2023 | Apr 30, 2023 | -$3.79M | – |
| FY2022 | Apr 30, 2022 | -$4.12M | – |
| FY2021 | Apr 30, 2021 | -$3.33M | – |
| FY2020 | Apr 30, 2020 | -$2.34M | – |
| FY2019 | Apr 30, 2019 | -$2.88M | – |
| FY2018 | Apr 30, 2018 | -$5.08M | – |
| FY2017 | Apr 30, 2017 | -$3.34M | – |
| FY2016 | Apr 30, 2016 | -$4.35M | – |
| FY2015 | Apr 30, 2015 | -$4.56M | – |
| FY2014 | Apr 30, 2014 | -$1.55M | – |
| FY2013 | Apr 30, 2013 | -$390.43K | – |
| FY2012 | Apr 30, 2012 | -$259.29K | – |
| FY2011 | Apr 30, 2011 | -$225.23K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | -$780.89K | – |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | -$1.39M | – |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | -$786.85K | – |
| Q4 FY2025CQ1 2025 | Apr 30, 2025 | -$1.04M | – |
| Q3 FY2025CQ4 2024 | Jan 31, 2025 | -$509.89K | – |
| Q2 FY2025CQ3 2024 | Oct 31, 2024 | -$1.05M | – |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | -$373.30K | -208.8% |
| Q4 FY2024CQ1 2024 | Apr 30, 2024 | -$332.96K | – |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | -$177.10K | – |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | -$1.98M | – |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | $342.96K | – |
| Q4 FY2023CQ1 2023 | Apr 30, 2023 | -$288.39K | – |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | -$541.70K | – |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | -$1.88M | – |
| Q1 FY2023CQ2 2022 | Jul 31, 2022 | -$1.08M | – |
| Q4 FY2022CQ1 2022 | Apr 30, 2022 | -$1.19M | – |
| Q3 FY2022CQ4 2021 | Jan 31, 2022 | -$298.65K | – |
| Q2 FY2022CQ3 2021 | Oct 31, 2021 | -$1.39M | – |
| Q1 FY2022CQ2 2021 | Jul 31, 2021 | -$1.24M | – |
| Q4 FY2021CQ1 2021 | Apr 30, 2021 | -$940.30K | – |
| Q3 FY2021CQ4 2020 | Jan 31, 2021 | -$589.13K | – |
| Q2 FY2021CQ3 2020 | Oct 31, 2020 | -$1.25M | – |
| Q1 FY2021CQ2 2020 | Jul 31, 2020 | -$551.00K | – |
| Q4 FY2020CQ1 2020 | Apr 30, 2020 | -$639.39K | – |
| Q3 FY2020CQ4 2019 | Jan 31, 2020 | -$352.22K | – |
| Q2 FY2020CQ3 2019 | Oct 31, 2019 | -$583.63K | – |
| Q1 FY2020CQ2 2019 | Jul 31, 2019 | -$763.14K | – |
| Q4 FY2019CQ1 2019 | Apr 30, 2019 | -$661.36K | – |
| Q3 FY2019CQ4 2018 | Jan 31, 2019 | -$676.50K | – |
| Q2 FY2019CQ3 2018 | Oct 31, 2018 | -$917.81K | – |
| Q1 FY2019CQ2 2018 | Jul 31, 2018 | -$622.24K | – |
| Q4 FY2018CQ1 2018 | Apr 30, 2018 | -$1.37M | – |
| Q3 FY2018CQ4 2017 | Jan 31, 2018 | -$1.17M | – |
| Q2 FY2018CQ3 2017 | Oct 31, 2017 | -$1.60M | – |
| Q1 FY2018CQ2 2017 | Jul 31, 2017 | -$935.57K | – |
| Q4 FY2017CQ1 2017 | Apr 30, 2017 | -$800.89K | – |
| Q3 FY2017CQ4 2016 | Jan 31, 2017 | -$925.30K | – |
| Q2 FY2017CQ3 2016 | Oct 31, 2016 | -$706.35K | – |
| Q1 FY2017CQ2 2016 | Jul 31, 2016 | -$906.93K | – |
See a number that looks wrong?